Cover Image
市場調查報告書

AstraZeneca PLC:產品平台分析

AstraZeneca Plc - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256068
出版日期 內容資訊 英文 369 Pages
訂單完成後即時交付
價格
Back to Top
AstraZeneca PLC:產品平台分析 AstraZeneca Plc - Product Pipeline Review - 2016
出版日期: 2016年03月30日 內容資訊: 英文 369 Pages
簡介

AstraZeneca PLC 在全世界的生物製藥企業,進行廣泛領域的一次療法及特殊醫療藥的設計、開發、製造、商品化。在該公司的產品中有生技藥品、處方藥、疫苗。處方藥主要在循環系統、代謝疾病(CVMD),癌症,消化器官、呼吸系統、發炎、自體免疫領域的3大重點領域投入力量。還有也致力於感染疾病、神經科學領域的疾病治療藥開發,該公司的先進治療藥用於全世界。

本報告提供AstraZeneca PLC的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

AstraZeneca Plc的基本資料

  • AstraZeneca Plc概要
  • 主要資訊
  • 企業資料

AstraZeneca Plc:R&D概要

  • 主要的治療範圍

AstraZeneca Plc:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
  • 轉出授權產品

AstraZeneca Plc:開發中產品概況

  • 處於最後階段的開發中產品
  • 處於臨床實驗階段的開發中產品
  • 處於初期階段的開發中產品

AstraZeneca Plc:開發階段不明的開發中產品

AstraZeneca Plc:藥物簡介

  • (saxagliptin + dapagliflozin)
  • (saxagliptin + metformin hydrochloride)
  • cangrelor
  • ceftaroline fosamil
  • dapagliflozin
  • lesinurad sodium
  • naloxegol oxalate
  • propofol
  • ticagrelor
  • vandetanib
  • (aclidinium bromide + formoterol fumarate)
  • (budesonide + formoterol fumarate + glycopyrrolate)
  • (ceftazidime + avibactam sodium)
  • (dapagliflozin + metformin hydrochloride + saxagliptin)
  • (glycopyrrolate + formoterol fumarate)
  • AZD-9291
  • AZD-9291 + durvalumab
  • budesonide ER
  • cediranib maleate
  • fulvestrant
  • gefitinib
  • glycopyrrolate
  • metreleptin
  • olaparib
  • omega-3-carboxylic acids
  • PT-005
  • quetiapine fumarate ER
  • roxadustat
  • selumetinib sulfate
  • AZD-3293
  • AZD-4547
  • (abediterol + inhaled corticosteroids)
  • (aztreonam lysine + avibactam sodium)
  • (ceftaroline fosamil + avibactam sodium)
  • abediterol
  • AZD-0914
  • AZD-1775
  • AZD-1981
  • AZD-2014
  • AZD-3241
  • AZD-4017
  • AZD-4901
  • AZD-5213
  • AZD-5363
  • AZD-7624
  • AZD-9150
  • exenatide
  • exenatide Once Monthly
  • HMPL-504
  • interferon beta-1a
  • lesogaberan
  • posizolid
  • PT-008
  • PT-009
  • RDEA-3170
  • sapitinib
  • saracatinib difumarate
  • AZD-5312
  • ARC-165395XX
  • AZD-0424
  • AZD-3759
  • AZD-3965
  • AZD-6738
  • AZD-7451
  • AZD-7594
  • AZD-7986
  • AZD-8108
  • AZD-8186
  • AZD-8835
  • AZD-8999
  • AZD-9496
  • dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide
  • disufenton sodium
  • LAS-40468
  • AC-163794
  • AZ-12260493
  • AZ-12441970
  • AZ-13483342
  • AZ-4217
  • AZ-4425
  • AZ-64
  • AZ-709
  • AZ-876
  • AZD-2098
  • AZD-2858
  • AZD-3463
  • AZD-3857
  • AZD-9708
  • AZGHS-22
  • AZGHS-38
  • Cephalosporin + Beta-Lactamase Inhibitor
  • CWGNC-41
  • Drug 1 for Cancer
  • Drug 2 for Cancer
  • Drug 3 for Cancer
  • Drug 4 for Cancer
  • Drug 5 for Cancer
  • Drug 6 for Cancer
  • Drugs 1 for Cancer
  • Drugs 2 for Cancer
  • KU-0060648
  • KU-59403
  • LAS-191351
  • LAS-194871
  • MMV-253
  • Monoclonal Antibody Conjugates for Cancer
  • NBTI-5463
  • NKTR-119
  • PL-8905
  • R-256
  • Small Molecule to Antagonize GPR103 for Obesity
  • Small Molecule to Antagonize Histamine 3 Receptor for Cognition
  • Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology
  • Small Molecule to Block Kv1.5 for Atrial Fibrillation
  • Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia
  • Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders
  • Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia
  • Small Molecules for Dyslipidemia and Hypertriglyceridemia
  • Small Molecules for Malaria
  • Small Molecules to Antagonize M3 Receptors for Respiratory Disorders
  • Small Molecules to Antagonize P2X3 for Chronic Pain
  • Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis
  • Small Molecules to Inhibit DNA GyrB for Tuberculosis
  • Small Molecules to Inhibit DprE1 for Mycobacterium Tuberculosis
  • AZ-10047130
  • AZ-27
  • AZ-465
  • AZ-82
  • AZD-3147
  • Drugs for Cardiovascular Diseases
  • HD-001
  • Small Molecule 1 for Malaria
  • Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes
  • Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis
  • Small Molecules for Cancer
  • Small Molecules for Tuberculosis
  • Small Molecules to Inhibit Acetohydroxyacid Synthase for Mycobacterium Infections
  • Small Molecules to Inhibit ATP Synthesis for Tuberculosis
  • Small Molecules to Inhibit Carboxypeptidase U for Thrombosis
  • Small Molecules to Inhibit DNA Gyrase B for Tuberculosis
  • Small Molecules to Inhibit DXP-Reductoisomerase for Malaria
  • Small Molecules to Inhibit MALT-1 for Oncology and Immunology
  • Small Molecules to Inhibit p38 MAP Kinase for Inflammatory Diseases
  • Small Molecules to Inhibit PLA2 for Undisclosed Indication
  • Small Molecules for Diabetic Nephropathy

AstraZeneca Plc:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AstraZeneca Plc:最近的開發平台趨勢

AstraZeneca Plc:暫停中的計劃

AstraZeneca Plc:開發中止的開發中產品

  • 開發中止的開發中產品簡介

AstraZeneca Plc:企業發表

AstraZeneca Plc:總公司和子公司的所在地

AstraZeneca Plc:主要製造設備

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08007CDB

Summary

Global Markets Direct's, 'AstraZeneca Plc - Product Pipeline Review - 2016', provides an overview of the AstraZeneca Plc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AstraZeneca Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AstraZeneca Plc
  • The report provides overview of AstraZeneca Plc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AstraZeneca Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AstraZeneca Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AstraZeneca Plc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AstraZeneca Plc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AstraZeneca Plc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AstraZeneca Plc Snapshot
    • AstraZeneca Plc Overview
    • Key Information
    • Key Facts
  • AstraZeneca Plc - Research and Development Overview
    • Key Therapeutic Areas
  • AstraZeneca Plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • AstraZeneca Plc - Pipeline Products Glance
  • AstraZeneca Plc - Late Stage Pipeline Products
  • AstraZeneca Plc - Clinical Stage Pipeline Products
  • AstraZeneca Plc - Early Stage Pipeline Products
  • AstraZeneca Plc - Drug Profiles
    • (avibactam + ceftazidime)
    • (dapagliflozin propanediol + saxagliptin)
    • (formoterol fumarate + glycopyrrolate)
    • (metformin hydrochloride + saxagliptin)
    • brodalumab
    • cangrelor tetrasodium
    • cediranib maleate
    • ceftaroline fosamil
    • dapagliflozin propanediol
    • osimertinib mesylate
    • propofol
    • ticagrelor
    • (aclidinium bromide + formoterol fumarate)
    • (budesonide + formoterol fumarate + glycopyrrolate)
    • (dapagliflozin propanediol + metformin hydrochloride + saxagliptin)
    • fulvestrant
    • gefitinib
    • glycopyrrolate
    • olaparib
    • omega-3-carboxylic acids
    • PT-009
    • quetiapine fumarate ER
    • roxadustat
    • selumetinib sulfate
    • AZD-3293
    • AZD-4547
    • (avibactam sodium + ceftaroline fosamil)
    • abediterol napadisylate
    • AZD-1775
    • AZD-1981
    • AZD-2014
    • AZD-3241
    • AZD-3759
    • AZD-4017
    • AZD-5363
    • AZD-7594
    • AZD-7624
    • AZD-9150
    • interferon beta-1a
    • lesogaberan
    • PT-008
    • RDEA-3170
    • sapitinib
    • saracatinib difumarate
    • savolitinib
    • Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease
    • AZD-5069
    • AZD-5312
    • (allopurinol + lesinurad)
    • (avibactam sodium + aztreonam lysine)
    • (insulin human + pramlintide acetate)
    • ARC-165395XX
    • AZD-0156
    • AZD-0424
    • AZD-3965
    • AZD-4076
    • AZD-5634
    • AZD-5718
    • AZD-6738
    • AZD-7451
    • AZD-7986
    • AZD-8108
    • AZD-8186
    • AZD-8835
    • AZD-8871
    • AZD-8999
    • AZD-9496
    • AZD-9567
    • dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide
    • LAS-40468
    • MEDI-7352
    • AC-163794
    • ADP-31417
    • ADP-71296
    • AZ-12260493
    • AZ-12441970
    • AZ-12861903
    • AZ-13483342
    • AZ-20
    • AZ-4217
    • AZ-4425
    • AZ-64
    • AZ-709
    • AZ-876
    • AZD-0449
    • AZD-2098
    • AZD-2858
    • AZD-3463
    • AZD-3857
    • AZD-4831
    • AZD-9708
    • CWGNC-41
    • Drug 1 for Cancer
    • Drug 2 for Cancer
    • Drug 3 for Cancer
    • Drug 4 for Cancer
    • Drug 5 for Cancer
    • Drug 6 for Cancer
    • HTL-1071
    • KU-59403
    • LAS-191351
    • LAS-194871
    • LCB-010200
    • MMV-253
    • Monoclonal Antibody Conjugates for Oncology
    • NBTI-5463
    • NKTR-119
    • OX-CLI
    • PL-8905
    • Small Molecule for Malaria
    • Small Molecule for Oncology
    • Small Molecule to Antagonize Histamine 3 Receptor for Cognition
    • Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology
    • Small Molecule to Block Kv1.5 for Atrial Fibrillation
    • Small Molecule to Inhibit DNA Gyrase for Streptococcal Pneumonia
    • Small Molecule to Inhibit PI3K Beta for Bleeding and Clotting Disorders
    • Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia
    • Small Molecules 1 for Malaria
    • Small Molecules for Dyslipidemia and Hypertriglyceridemia
    • Small Molecules to Antagonize GPR103 for Obesity
    • Small Molecules to Antagonize M3 Receptors for Respiratory Disorders
    • Small Molecules to Antagonize P2X3 for Chronic Pain
    • Small Molecules to Inhibit CDK9 for Inflammatory Pain and Rheumatoid Arthritis
    • Small Molecules to Inhibit DNA GyrB for Tuberculosis
    • Small Molecules to Inhibit DprE1 for Tuberculosis
    • Synthetic Peptide for Neuropathic Pain
    • VU-0467154
    • AZ-0108
    • AZ-12201182
    • AZ-27
    • AZ-465
    • AZ-6142
    • AZ-82
    • AZD-3147
    • Drugs for Cardiovascular Diseases
    • HD-001
    • Small Molecule 1 for Malaria
    • Small Molecule to Inhibit 11beta-HSD-1 for Type 2 Diabetes
    • Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis
    • Small Molecules for Diabetic Nephropathy
    • Small Molecules for Tuberculosis
    • Small Molecules to Inhibit Acetohydroxyacid Synthase for Mycobacterium Infections
    • Small Molecules to Inhibit ATP Synthesis for Tuberculosis
    • Small Molecules to Inhibit Carboxypeptidase U for Thrombosis
    • Small Molecules to Inhibit DNA Gyrase B for Tuberculosis
    • Small Molecules to Inhibit DXP-Reductoisomerase for Malaria
    • Small Molecules to Inhibit MALT-1 for Oncology and Autoimmune Disorders
    • Small Molecules to Inhibit p38alpha MAP Kinase for Inflammatory Diseases
    • Small Molecules to Inhibit PLA2 for Undisclosed Indication
  • AstraZeneca Plc - Pipeline Analysis
    • AstraZeneca Plc - Pipeline Products by Target
    • AstraZeneca Plc - Pipeline Products by Route of Administration
    • AstraZeneca Plc - Pipeline Products by Molecule Type
    • AstraZeneca Plc - Pipeline Products by Mechanism of Action
  • AstraZeneca Plc - Recent Pipeline Updates
  • AstraZeneca Plc - Dormant Projects
  • AstraZeneca Plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • AstraZeneca Plc - Company Statement
  • AstraZeneca Plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • AstraZeneca Plc - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AstraZeneca Plc, Key Information
  • AstraZeneca Plc, Key Facts
  • AstraZeneca Plc - Pipeline by Indication, 2016
  • AstraZeneca Plc - Pipeline by Stage of Development, 2016
  • AstraZeneca Plc - Monotherapy Products in Pipeline, 2016
  • AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016
  • AstraZeneca Plc - Partnered Products in Pipeline, 2016
  • AstraZeneca Plc - Partnered Products/ Combination Treatment Modalities, 2016
  • AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016
  • AstraZeneca Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • AstraZeneca Plc - Pre-Registration, 2016
  • AstraZeneca Plc - Filing rejected/Withdrawn, 2016
  • AstraZeneca Plc - Phase III, 2016
  • AstraZeneca Plc - Phase II, 2016
  • AstraZeneca Plc - Phase I, 2016
  • AstraZeneca Plc - Preclinical, 2016
  • AstraZeneca Plc - Discovery, 2016
  • AstraZeneca Plc - Pipeline by Target, 2016
  • AstraZeneca Plc - Pipeline by Route of Administration, 2016
  • AstraZeneca Plc - Pipeline by Molecule Type, 2016
  • AstraZeneca Plc - Pipeline Products by Mechanism of Action, 2016
  • AstraZeneca Plc - Recent Pipeline Updates, 2016
  • AstraZeneca Plc - Dormant Developmental Projects,2016
  • AstraZeneca Plc - Discontinued Pipeline Products, 2016
  • AstraZeneca Plc, Subsidiaries
  • AstraZeneca Plc, Key Manufacturing Facilities

List of Figures

  • AstraZeneca Plc - Pipeline by Top 10 Indication, 2016
  • AstraZeneca Plc - Pipeline by Stage of Development, 2016
  • AstraZeneca Plc - Monotherapy Products in Pipeline, 2016
  • AstraZeneca Plc - Combination Treatment Modalities in Pipeline, 2016
  • AstraZeneca Plc - Partnered Products in Pipeline, 2016
  • AstraZeneca Plc - Out-Licensed Products in Pipeline, 2016
  • AstraZeneca Plc - Pipeline by Top 10 Target, 2016
  • AstraZeneca Plc - Pipeline by Route of Administration, 2016
  • AstraZeneca Plc - Pipeline by Molecule Type, 2016
  • AstraZeneca Plc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top